Hoping Drugs Take Root, Alder Raises $38 Million Round

The Bothell, Wash.-based antibody developer will study a Phase II interleukin-6 inhibitor in cancer indications, and will bring a new migraine drug into the clinic. The IL-6 drug is already partnered with BMS in a lucrative deal for autoimmune indications.